Using intravital microscopy to observe bevacizumab-mediated anti-angiogenesis in human head and neck squamous cell carcinoma xenografts

Yamatodani, Takashi; Holmqvist, Bo; Kjellén, Elisabeth; Johnsson, Anders; Mineta, Hiroyuki; Wennerberg, Johan

doi:10.3109/00016489.2012.699195

Cited by 3 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study from our laboratory showed that high VEGF expression was significantly related to a decrease in survival, whereas loss of VEGF results in a significantly improved prognosis . Furthermore, Yamatodani et al reported significant inhibitions of bevacizumab on angiogenesis and cancer cell survival in HNSCC . Our results indicate that hypermethylation of GALR2 with a high expression of VEGF is associated with a DFS rate of 10.5%, compared with 52.2% for other conditions (log‐rank test, P = .0096) (Fig.…”

Section: Discussionsupporting

confidence: 54%

Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer

Misawa

Kanazawa

et al. 2013

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 54%

Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer

Misawa

Kanazawa

et al. 2013

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Innovative drug delivery systems visualized by IVM utilizing nanoparticles to enhance tumor responses offer unique approaches to augment the efficacy of chemotherapeutic agents [ 16 , 64 , 65 ]. Tumor vessel responses to anti-angiogenic drugs such as bevacizumab can also be directly observed over time with IVM [ 55 , 66 ], which have shown partial restoration of normal vessel permeability and interstitial fluid pressures that equate to enhanced anti-tumor responses. In summary, IVM has and continues to provide novel information regarding tumor vasculature, blood flow, and drug delivery in preclinical cancer models.…”

Section: Ivm In the Study Of Tumor Vasculaturementioning

confidence: 99%

Intravital microscopy in the study of the tumor microenvironment: from bench to human application

et al. 2018

View full text Add to dashboard Cite

Intravital microscopy (IVM) is a dynamic imaging modality that allows for the real time observation of biologic processes in vivo, including angiogenesis and immune cell interactions. In the setting of preclinical cancer models, IVM has facilitated an understanding of the tumor associated vasculature and the role of effector immune cells in the tumor microenvironment. Novel approaches to apply IVM to human malignancies have thus far focused on cancer diagnosis and tumor vessel characterization, but have the potential to provide advances in the field of personalized medicine by identifying individual patients who may respond to systemically delivered chemotherapeutic drugs or immunotherapeutic agents. In this review, we highlight the role that IVM has had in investigating tumor vasculature and the tumor microenvironment in preclinical studies and discuss its current and future applications to directly observe human tumors.

show abstract

“…Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, was the first anti-angiogenesis agent to receive US Food and Drug Administration approval in oncology [ 16 ]. Numerous studies of the bevacizumab showed promise in patients with squamous cell carcinoma of the head and neck (SCCHN) [ 17 , 18 ]. Nylfot, MJ et al reported that bevacizumab could reduce tumor proliferative capacity of SCCHN, and combined bevacizumab with cisplatin-based chemo-radiation therapy for SCCHN revealed safe and significant responses [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Dramatic response of CTNNB1 and VEGFR-2 mutant temporal bone squamous cell carcinoma to bevacizumab in combination with pemetrexed

et al. 2017

View full text Add to dashboard Cite

High recurrence rates and poor survival rates for late stage/advanced temporal bone squamous cell carcinoma with the standard treatments continues to be a significant challenge to otolaryngologists. Targeted therapy for temporal bone squamous cell carcinoma after relapse has not been reported. Here we present a 58-year-old man who was diagnosed with recurrent temporal bone squamous cell carcinoma and treated with a regimen developed using whole exome sequencing. Somatic mutations in genes encoding catenin beta 1 and vascular endothelial growth factor receptor 2 were identified in the patient’s tumor sample compared to the normal tissue. The patient was then treated with Bevacizumab in combination with pemetrexed. After two weeks of treatment, tumor volume was reduced by 95% measured by MRI, and the Visual Analogue Scale headache scores went down from 10/10 to 2/10. Our results reveal novel gene mutations of temporal bone squamous cell carcinoma and demonstrate, for the first time, an effective targeted therapy for temporal bone squamous cell carcinoma. The successful treatment regimen of bevacizumab and pemetrexed may provide a new treatment option for treating recurrent temporal bone squamous cell carcinoma that fails to respond to conventional tumor resection, radiotherapy, and/or chemotherapy.

show abstract

Using intravital microscopy to observe bevacizumab-mediated anti-angiogenesis in human head and neck squamous cell carcinoma xenografts

Abstract: We found significant effects of bevacizumab on angiogenesis and cancer cell survival in HNSCC. Repeated injections of bevacizumab were found to provide the greatest effects.

Cited by 3 publications

References 17 publications

Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer

Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer

Intravital microscopy in the study of the tumor microenvironment: from bench to human application

Dramatic response of CTNNB1 and VEGFR-2 mutant temporal bone squamous cell carcinoma to bevacizumab in combination with pemetrexed

Contact Info

Product

Resources

About